MEB-1170
Opioid Use Disorder
Phase 1Active
Key Facts
About Mebias Discovery
Mebias Discovery is a private, preclinical-stage biotech using a unique conformation-driven NMR platform to discover safer GPCR-targeting drugs. The company's lead asset, MEB-1170, is a mu-opioid receptor-targeted therapy for opioid use disorder (OUD) that has entered Phase 1 trials with support from the NIH's NIDA. Beyond this, Mebias is developing S1PR1 agonists for neuropathic pain and neuroinflammation, positioning itself at the intersection of addiction medicine and neurology. The company is backed by a mix of venture capital, angel investors, and significant non-dilutive grant funding from U.S. government agencies.
View full company profileTherapeutic Areas
Other Opioid Use Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| TRV734 | Trevena | Phase 1 |
| FP-004 (SIF Formulation) | Foresee Pharmaceuticals | Preclinical |
| Vaxine Opioid Addiction Vaccine | Vaxine | Preclinical |
| Safer Ibogaine Analogs | Gilgamesh Pharmaceuticals | Pre-clinical/Research |
| AM-510 | Aion Medicines | Discovery |
| Naltrexone Implant | Delpor | Phase 1 |
| Platform Expansion | Amygdala Neurosciences | Research |
| Undisclosed OUD Program | Epiodyne | Pre-clinical |
| AQL™-Naltrexone | Plumb Pharmaceuticals | Pre-clinical |
| SUBLOCADE® | Indivior PLC | Marketed |